A Phase 4 interventional study of Secukinumab 300 mg and Placebo in Chronic Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 34th largest by enrollment, is one of 4 that started in 2016, is one of 17 in phase 4, and was the 33rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 38th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2016, is one of 6 in phase 4, and was the 41st registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
Drug: Secukinumab 300 mg
Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive.
Biological: Placebo
Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive. The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits. The injections not occurring on days of study visits were done by the patients (or caregivers) at home.
Also known as: AIN457 300 mg
Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive. The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits. The injections not occurring on days of study visits were done by the patients (or caregivers) at home.
Aortic Vascular Inflammation as Measured by FDG-PET/CT
Change from baseline in the target to background ratio from the whole aorta. Effect of secukinumab 300 mg subcutaneous (sc) compared to placebo on aortic vascular inflammation with respect to the change from baseline in the target (arterial vascular uptake) to background (venous blood pool) ratio from the aorta. The primary analysis time point was at Week 12. Increased aortic vascular inflammation as measured by (18F) fluorodeoxyglucose positron emission tomography with computer assisted tomography (FDG-PET/CT)
Time frame: baseline, 12 weeks
Change in Adiponectin Total
Change from baseline in Adiponectin to measure adiposity
Time frame: baseline, 12 weeks
Change in Apolipoprotein B
Change from baseline in Apolipoprotein B levels, a marker predictive of diabetes
Time frame: baseline, 12 weeks
Change in CRP
Change from baseline in C reactive protein (CRP), a measure of inflammation
Time frame: baseline, 12 weeks
Change in Cholesterol
Change from baseline in Cholesterol level
Time frame: baseline, 12 weeks
Change in Fetuin A
Change from baseline in Fetuin A, a marker predictive of diabetes
Time frame: baseline, 12 weeks
Change in Ferritin
Change from baseline in Ferritin, a marker predictive of diabetes
Time frame: baseline, 12 weeks
Change in GlycA
Change from baseline in glycoprotein acetylation (GlycA), a marker of inflammation
Time frame: baseline, 12 weeks
Change in HDL Cholesterol
Change from baseline in High Density Lipoprotein (HDL) Cholesterol, a cardiometabolic biomarker
Time frame: baseline, 12 weeks
Change in HDL Function (Cholesterol Efflux)
Change from baseline in High Density Lipoprotein (HDL) Cholesterol (cholesterol efflux) , a cardiometabolic biomarker Ratio of the pleated serum to removal of Cholesterol
Time frame: baseline, 12 weeks
HDL Particle Total
Change from baseline in High Density Lipoprotein (HDL) Cholesterol Particle Total
Time frame: baseline, 12 weeks
HDL Size
Change from baseline in High Density Lipoprotein (HDL) Cholesterol size
Time frame: baseline, 12 weeks
HOMA-IR
Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) Insulin \[uIU/mL (mU/L)\] x Glucose (mg/dL) = HOMA-IR
Time frame: baseline, 12 weeks
Change in IL-2 Receptor A
Interleukin-2 Receptor A (IL-2RA) is a marker predictive of diabetes
Time frame: baseline, 12 weeks
Change in IL-18
Interleukin-18 (IL-18) is a marker predictive of diabetes
Time frame: baseline, 12 weeks
Change in IL-6
Interleukin 6 (IL-6) is a marker of inflammation
Time frame: baseline, 12 weeks
Change in Intermediate-Density Lipoprotein (IDL) Particle
Intermediate-density lipoprotein (IDL) particle is a marker of cardiometabolic function
Time frame: baseline, 12 weeks
Change LDL Cholesterol
Change from baseline in Low-Density Lipoprotein (LDL) Cholesterol as a marker of cardiometabolic function
Time frame: baseline, 12 weeks
Change in Leptin
Change from baseline in Leptin a marker of adiposity
Time frame: baseline, 12 weeks
LDL Particle Total
Change from baseline in Low Density Lipoprotein (LDL) Cholesterol Particle Total
Time frame: baseline, 12 weeks
LDL Size
Change from baseline in Low Density Lipoprotein (LDL) Cholesterol size
Time frame: baseline, 12 weeks
Change in Triglycerides
Triglycerides are a marker of cardiometabolic function
Time frame: baseline, 12 weeks
Change in TNF-α
Change in Tumor necrosis factor (TNF, tumor necrosis factor alpha, TNFα is a marker of inflammation Also written as TNF-alpha
Time frame: baseline, 12 weeks
Change VLDL Particle Total
Change in Very-low-density lipoprotein (VLDL) cholesterol level
Time frame: baseline, 12 weeks
VLDL Size
Change from baseline in Very Low Density Lipoprotein (VLDL) Cholesterol size
Time frame: baseline, 12 weeks
Area and Severity Index 75 (PASI 75)
Percentage of participants with PASI75 response (yes, no) PASI75 response = at least a 75% improvement (reduction) in PASI score compared to baseline Psoriasis Area and Severity Index ( PASI) is a tool for measuring the severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).
Time frame: week 12
Psoriasis Area and Severity Index 90 (PASI 90)
Percentage of participants with PASI90 response (yes, no) PASI90 response = at least a 90\& improvement (reduction) in PASI score compared to baseline
Time frame: week 12
Psoriasis Area and Severity Index 100 (PASI100)
Percentage of participants with PASI100 response (yes, no) PASI100 response = complete clearing of psoriasis
Time frame: week 12
Investigator's Global Assessment Modified 2011 (IGA Mod 2011) Score of 0 or 1
percentage of participants with IGA mod 2011 score of 0 or 1 (yes, no) Investigator's Global Assessment modified 2011 (IGA mod 2011) score of 0 or 1 Statistical analysis (Cochran-Mantel-Haenszel test) of Novartis Investigator's Global Assessment Modified 2011 0 or 1 response by visit (Non-responder Imputation)
Time frame: week 12
Dermatology Life Quality Index (DLQI) Total Score
Change from baseline in the DLQI total score Summary of analysis of change from baseline in DLQI at Week 12 and statistical analysis (using Analysis of Covariance) of change from baseline in DLQI at Week 12 The higher the score, the more quality of life is impaired. 0 - 1 no effect at all on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life
Time frame: baseline, 12 weeks
Randomized Set consisted of all 91 participants who were randomly assigned to a treatment group
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 46 | 45 |
| Completed | 44 | 42 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 44 | 42 |
| Completed | 41 | 37 |
| Not completed | 3 | 5 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
Change from baseline in the target to background ratio from the whole aorta. Effect of secukinumab 300 mg subcutaneous (sc) compared to placebo on aortic vascular inflammation with respect to the change from baseline in the target (arterial vascular uptake) to background (venous blood pool) ratio from the aorta. The primary analysis time point was at Week 12. Increased aortic vascular inflammation as measured by (18F) fluorodeoxyglucose positron emission tomography with computer assisted tomography (FDG-PET/CT)
| target to background ratio (TBR) | Secukinumab | Placebo |
|---|---|---|
| Baseline | 1.6615 ± 0.37380 | 1.6333 ± 0.33228 |
| Change from Baseline at Week 12 | 0.0143 ± 0.25520 | 0.0655 ± 0.28086 |
Change from baseline in Adiponectin to measure adiposity
| ng/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 18799.0 ± 18608.48 | 19475.00 ± 18343.00 |
| Change from Baseline at Week 12 | 1594.90 ± 15146.84 | -1076.40 ± 14565.60 |
Change from baseline in Apolipoprotein B levels, a marker predictive of diabetes
| ng/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 0.1014 ± 0.04651 | 0.1033 ± 0.04451 |
| Change from Baseline at Week 12 | 0.0020 ± 0.06331 | 0.0017 ± 0.04835 |
Change from baseline in C reactive protein (CRP), a measure of inflammation
| mg/L | Secukinumab | Placebo |
|---|---|---|
| Baseline | 6.1525 ± 8.23016 | 7.8676 ± 7.59860 |
| Change from Baseline at Week 12 | -1.0016 ± 9.45281 | 1.1622 ± 15.84088 |
Change from baseline in Cholesterol level
| mg/dL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 179.350 ± 30.01243 | 178.707 ± 38.92573 |
| Change from Baseline at Week 12 | 10.6000 ± 30.27379 | -8.4878 ± 35.18247 |
Change from baseline in Fetuin A, a marker predictive of diabetes
| ng/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 988677.800781 ± 488494.3491043 | 1169947.724848 ± 79644.6884632 |
| Change from Baseline at Week 12 | 90810.212003 ± 444791.4700461 | 45731.298018 ± 452743.5932412 |
Change from baseline in Ferritin, a marker predictive of diabetes
| ng/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 111.953 ± 91.17931 | 122.040 ± 114.8715 |
| Change from Baseline at Week 12 | -6.1006 ± 60.71995 | -17.118 ± 63.86703 |
Change from baseline in glycoprotein acetylation (GlycA), a marker of inflammation
| μmol/L | Secukinumab | Placebo |
|---|---|---|
| Baseline | 413.860 ± 65.34929 | 439.622 ± 60.44873 |
| Change from Baseline at Week 12 | 0.5152 ± 59.46394 | -1.5420 ± 40.25958 |
Change from baseline in High Density Lipoprotein (HDL) Cholesterol, a cardiometabolic biomarker
| mg/dL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 43.3000 ± 10.20357 | 43.0732 ± 12.52276 |
| Change from Baseline at Week 12 | -0.7500 ± 8.80195 | -1.1220 ± 8.10924 |
Change from baseline in High Density Lipoprotein (HDL) Cholesterol (cholesterol efflux) , a cardiometabolic biomarker Ratio of the pleated serum to removal of Cholesterol
| ratio | Secukinumab | Placebo |
|---|---|---|
| Baseline | 0.9535 ± 0.18986 | 1.0456 ± 0.17819 |
| Change from Baseline at Week 12 | 0.1473 ± 0.23262 | 0.0541 ± 0.21902 |
Change from baseline in High Density Lipoprotein (HDL) Cholesterol Particle Total
| μmol/L | Secukinumab | Placebo |
|---|---|---|
| Baseline | 29.2875 ± 5.38184 | 29.3634 ± 6.27442 |
| Change from Baseline at Week 12 | -0.1375 ± 5.22900 | -0.1707 ± 5.12973 |
Change from baseline in High Density Lipoprotein (HDL) Cholesterol size
| nm | Secukinumab | Placebo |
|---|---|---|
| Baseline | 8.9350 ± 0.53280 | 8.9585 ± 0.56656 |
| Change from Baseline at Week 12 | 0.0500 ± 0.47932 | 0.0073 ± 0.34161 |
Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) Insulin \[uIU/mL (mU/L)\] x Glucose (mg/dL) = HOMA-IR
| HOMA-IR units | Secukinumab | Placebo |
|---|---|---|
| Baseline | 3.4901 ± 3.02479 | 5.5112 ± 6.22334 |
| Change from Baseline at Week 12 | 0.9563 ± 2.23669 | -1.2764 ± 5.13505 |
Interleukin-2 Receptor A (IL-2RA) is a marker predictive of diabetes
| pg/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 25.5554 ± 59.47232 | 21.0665 ± 61.46295 |
| Change from Baseline at Week 12 | -3.3606 ± 38.52458 | -1.1162 ± 6.31189 |
Interleukin-18 (IL-18) is a marker predictive of diabetes
| pg/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 1259.45 ± 1910.327 | 1308.47 ± 2454.672 |
| Change from Baseline at Week 12 | 34555.1 ± 231199.6 | -627.77 ± 1874.377 |
Interleukin 6 (IL-6) is a marker of inflammation
| pg/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 5.6477 ± 20.81242 | 1.6658 ± 1.50954 |
| Change from Baseline at Week 12 | 0.1334 ± 29.35524 | -0.0900 ± 1.78692 |
Intermediate-density lipoprotein (IDL) particle is a marker of cardiometabolic function
| nmol/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 284.350 ± 179.6482 | 271.049 ± 155.7413 |
| Change from Baseline at Week 12 | 47.0500 ± 167.6253 | 2.3902 ± 160.6046 |
Change from baseline in Low-Density Lipoprotein (LDL) Cholesterol as a marker of cardiometabolic function
| mg/dL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 122.475 ± 28.86040 | 121.049 ± 36.39708 |
| Change from Baseline at Week 12 | 9.9750 ± 29.84532 | -6.2927 ± 34.42401 |
Change from baseline in Leptin a marker of adiposity
| pg/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 19913.4 ± 21835.66 | 36813.3 ± 62138.25 |
| Change from Baseline at Week 12 | -1886.0 ± 11701.00 | -5595.9 ± 17042.08 |
Change from baseline in Low Density Lipoprotein (LDL) Cholesterol Particle Total
| nmol/L | Secukinumab | Placebo |
|---|---|---|
| Baseline | 1236.35 ± 317.9542 | 1263.00 ± 447.3457 |
| Change from Baseline at Week 12 | 114.250 ± 294.8695 | -111.39 ± 343.2109 |
Change from baseline in Low Density Lipoprotein (LDL) Cholesterol size
| nm | Secukinumab | Placebo |
|---|---|---|
| Baseline | 21.2200 ± 0.74977 | 21.1171 ± 0.76384 |
| Change from Baseline at Week 12 | -0.0025 ± 0.70036 | 0.1439 ± 0.53807 |
Triglycerides are a marker of cardiometabolic function
| mg/dL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 123.200 ± 52.90398 | 125.293 ± 79.10633 |
| Change from Baseline at Week 12 | 11.5000 ± 62.56279 | -10.732 ± 60.25281 |
Change in Tumor necrosis factor (TNF, tumor necrosis factor alpha, TNFα is a marker of inflammation Also written as TNF-alpha
| pg/mL | Secukinumab | Placebo |
|---|---|---|
| Baseline | 2.3919 ± 1.79049 | 2.8089 ± 4.11492 |
| Change from Baseline at Week 12 | -0.3577 ± 1.52948 | -0.9818 ± 3.85715 |
Change in Very-low-density lipoprotein (VLDL) cholesterol level
| nmol/L | Secukinumab | Placebo |
|---|---|---|
| Baseline | 52.9125 ± 26.92102 | 54.5829 ± 27.57024 |
| Change from Baseline at Week 12 | 3.2500 ± 28.56421 | 3.2024 ± 25.40299 |
Change from baseline in Very Low Density Lipoprotein (VLDL) Cholesterol size
| nm | Secukinumab | Placebo |
|---|---|---|
| Baseline | 51.5650 ± 9.11152 | 50.1195 ± 9.51641 |
| Change from Baseline at Week 12 | -0.3950 ± 9.30271 | -0.7927 ± 7.72572 |
Percentage of participants with PASI75 response (yes, no) PASI75 response = at least a 75% improvement (reduction) in PASI score compared to baseline Psoriasis Area and Severity Index ( PASI) is a tool for measuring the severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).
| percentage of participants | Secukinumab | Placebo |
|---|---|---|
| Area and Severity Index 75 (PASI 75) | 84.8 | 0.0 |
Percentage of participants with PASI90 response (yes, no) PASI90 response = at least a 90\& improvement (reduction) in PASI score compared to baseline
| percentage of participants | Secukinumab | Placebo |
|---|---|---|
| Psoriasis Area and Severity Index 90 (PASI 90) | 73.9 | 0.0 |
Percentage of participants with PASI100 response (yes, no) PASI100 response = complete clearing of psoriasis
| percentage of participants | Secukinumab | Placebo |
|---|---|---|
| Psoriasis Area and Severity Index 100 (PASI100) | 37.0 | 0.0 |
percentage of participants with IGA mod 2011 score of 0 or 1 (yes, no) Investigator's Global Assessment modified 2011 (IGA mod 2011) score of 0 or 1 Statistical analysis (Cochran-Mantel-Haenszel test) of Novartis Investigator's Global Assessment Modified 2011 0 or 1 response by visit (Non-responder Imputation)
| percentage of participants | Secukinumab | Placebo |
|---|---|---|
| Investigator's Global Assessment Modified 2011 (IGA Mod 2011) Score of 0 or 1 | 78.3 | 0.0 |
Change from baseline in the DLQI total score Summary of analysis of change from baseline in DLQI at Week 12 and statistical analysis (using Analysis of Covariance) of change from baseline in DLQI at Week 12 The higher the score, the more quality of life is impaired. 0 - 1 no effect at all on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life
| scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Baseline | 12.30 ± 7.65 | 12.6 ± 7.21 |
| Change from baseline at Week 12 | -9.4 ± 7.91 | -0.5 ± 3.97 |
Collected over Adverse Events (AEs) were collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg | 0/46 (0%) | 5/46 (10.9%) | 21/46 (45.7%) |
| Placebo/Secukinumab 300 mg | 0/45 (0%) | 0/45 (0%) | 18/45 (40%) |
| Total | 0/91 (0%) | 5/91 (5.5%) | 39/91 (42.9%) |
| Event | Secukinumab 300 mg | Placebo/Secukinumab 300 mg | Total |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/46 | 0/45 | 1/91 |
| Rib fractureInjury, poisoning and procedural complications | 1/46 | 0/45 | 1/91 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/46 | 0/45 | 1/91 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/46 | 0/45 | 1/91 |
| Aortic stenosisVascular disorders | 1/46 | 0/45 | 1/91 |
| Event | Secukinumab 300 mg | Placebo/Secukinumab 300 mg | Total |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/46 | 7/45 | 16/91 |
| Upper respiratory tract infectionInfections and infestations | 6/46 | 4/45 | 10/91 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/46 | 3/45 | 8/91 |
| HeadacheNervous system disorders | 0/46 | 4/45 | 4/91 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/46 | 4/45 | 5/91 |
| SinusitisInfections and infestations | 0/46 | 3/45 | 3/91 |
| DizzinessNervous system disorders | 1/46 | 3/45 | 4/91 |
| DiarrhoeaGastrointestinal disorders | 3/46 | 2/45 | 5/91 |
| BronchitisInfections and infestations | 3/46 | 0/45 | 3/91 |
| Age, Categorical(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 41 | 39 | 80 |
| >=65 years | 5 | 6 | 11 |
| Sex: Female, Male(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Female | 13 | 17 | 30 |
| Male | 33 | 28 | 61 |
| Race/Ethnicity, Customized(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Caucasian | 36 | 36 | 72 |
| Black | 1 | 3 | 4 |
| Asian | 6 | 2 | 8 |
| Other | 3 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2016 to primary completion in Apr 2017, 14 months.
Results were first posted in Jul 2019, 2 years 2 months after primary completion. A results delay was requested in Feb 2018.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab